Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Fifth Avenue, Suite 1400, New York, NY
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 176 % +113%
Debt-to-equity 133 %
Return On Equity -209 % -116%
Return On Assets -89.5 % +67.6%
Operating Margin -22.9K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142M shares +33.7%
Common Stock, Shares, Outstanding 137M shares +61.7%
Entity Public Float 478M USD +648%
Common Stock, Value, Issued 35K USD +338%
Weighted Average Number of Shares Outstanding, Basic 140M shares +65.6%
Weighted Average Number of Shares Outstanding, Diluted 140M shares +65.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 455K USD
Research and Development Expense 48.7M USD -9.57%
General and Administrative Expense 56M USD +172%
Operating Income (Loss) -104M USD -61.6%
Nonoperating Income (Expense) -1.33M USD +97.6%
Net Income (Loss) Attributable to Parent -106M USD +11.8%
Earnings Per Share, Basic -0.76 USD/shares +46.5%
Earnings Per Share, Diluted -0.76 USD/shares +46.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79.4M USD +59.1%
Cash, Cash Equivalents, and Short-term Investments 22.9M USD -58.9%
Other Assets, Current 461K USD +6.71%
Assets, Current 83.6M USD +53.8%
Operating Lease, Right-of-Use Asset 2.79M USD +525%
Assets 86.7M USD +58.1%
Accounts Payable, Current 4.43M USD +154%
Contract with Customer, Liability, Current 212K USD -68.2%
Liabilities, Current 27.3M USD -61.7%
Operating Lease, Liability, Noncurrent 2.39M USD +6187%
Liabilities 29.7M USD -58.8%
Retained Earnings (Accumulated Deficit) -574M USD -22.5%
Stockholders' Equity Attributable to Parent 57M USD
Liabilities and Equity 86.7M USD +58.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD -171%
Net Cash Provided by (Used in) Financing Activities 115M USD
Net Cash Provided by (Used in) Investing Activities 13.9M USD +45.6%
Common Stock, Shares Authorized 250M shares +25%
Common Stock, Shares, Issued 137M shares +61.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 96.6M USD +1443%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79.4M USD +59.1%
Deferred Tax Assets, Valuation Allowance 181M USD +19.5%
Deferred Tax Assets, Gross 182M USD +20%
Operating Lease, Liability 2.8M USD +499%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -106M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid 3.92M USD +701%
Operating Lease, Liability, Current 406K USD -5.36%
Lessee, Operating Lease, Liability, to be Paid, Year Two 803K USD +3391%
Lessee, Operating Lease, Liability, to be Paid, Year One 787K USD +76.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +117%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.12M USD +5005%
Lessee, Operating Lease, Liability, to be Paid, Year Three 803K USD
Deferred Tax Assets, Operating Loss Carryforwards 115M USD +22.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 823K USD
Additional Paid in Capital 631M USD +39.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 870K USD +526%
Share-based Payment Arrangement, Expense 15.6M USD +112%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%